Document is current
Any future updates will be listed below
-
Authors
Xue, Xuemin
Fu, Libing
Qiu, Tian
Cao, Zheng
Wang, Xiaojun
Rao, Wei
Luo, Yiyang
He, Lejian
Feng, Xiaoli https://orcid.org/0000-0001-5663-6006
-
Funding
Funding for this research was provided by:
Beijing Hope Run Special Fund of Cancer Foundation of China (LC2021A21)
- License Information
-
More Information
Article History
Received: 6 June 2022
Revised: 28 September 2022
Accepted: 15 October 2022
First Online: 16 November 2022
Declarations
:
: This study was conducted in accordance with the ethics of the Declaration of Helsinki. Due to the retrospective study, the data regarding pathological parameters and treatments were acquired by means of medical record consultation. Thus, the need for consent was waived by the Independent Ethics Committee of Cancer Hospital, Chinese Academy of Medical Sciences, National GCP Center for Anticancer Drugs (22/021–3222).
: The authors declare no competing interests.
